Daniel Patrick O’day Sells 15,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the transaction, the chief executive officer directly owned 577,133 shares in the company, valued at approximately $85,785,049.12. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, August 3rd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00.
• On Wednesday, July 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00.

Gilead Sciences Trading Up 1.1%

GILD opened at $151.22 on Friday. The stock’s fifty day moving average is $136.21 and its two-hundred day moving average is $136.42. The company has a market capitalization of $187.51 billion, a P/E ratio of -56.64 and a beta of 0.33. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the prior year, the business earned $2.01 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s dividend payout ratio is -122.85%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Truist Financial reduced their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Morgan Stanley cut their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings lowered Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $158.04.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts raised Gilead’s earnings forecasts and upgraded the stock to “Strong Buy.” Zacks increased its 2027 quarterly EPS estimates and lifted its full-year forecast to $9.36 from $9.30. It also raised its FY2028 estimate to $9.66 from $9.58, suggesting expectations for improving profitability. Zacks upgrade and earnings estimates
• Positive Sentiment: Gilead’s latest results provided a favorable foundation for the rally. The company reported quarterly revenue of $7.80 billion, above the $7.40 billion consensus estimate, while its loss per share was narrower than expected. Revenue increased 10.6% year over year, giving investors confidence in the business despite currently negative reported earnings. Gilead post-earnings performance
• Positive Sentiment: A partner-backed stomach-cancer trial reached completion, creating a potential immuno-oncology catalyst. The milestone involving Arcus-supported research could provide important future data for Gilead’s oncology strategy, although the eventual investment impact depends on trial results and regulatory progress. Gilead cancer trial milestone
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The sale reduced his ownership by 2.53%, but it was conducted under a pre-arranged Rule 10b5-1 trading plan, making it a limited bearish signal. SEC insider trading filing

Institutional Trading of Gilead Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in GILD. Range Advisory LLC raised its stake in Gilead Sciences by 15.5% in the second quarter. Range Advisory LLC now owns 2,668 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 359 shares during the last quarter. Tucker Asset Management LLC grew its stake in shares of Gilead Sciences by 6.5% during the second quarter. Tucker Asset Management LLC now owns 3,970 shares of the biopharmaceutical company’s stock worth $502,000 after acquiring an additional 242 shares during the last quarter. HighTower Advisors LLC increased its holdings in shares of Gilead Sciences by 5.8% during the second quarter. HighTower Advisors LLC now owns 1,534,627 shares of the biopharmaceutical company’s stock valued at $193,885,000 after acquiring an additional 84,450 shares in the last quarter. Groupe la Francaise increased its holdings in shares of Gilead Sciences by 30.9% during the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after acquiring an additional 11,712 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $130,420,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.